Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulbenicillin is a semisynthetic penicillin antibiotic belonging to the carboxypenicillin subclass. It is structurally related to ticarcillin and carbenicillin, and was developed for use against Gram-negative bacteria, particularly Pseudomonas aeruginosa. Sulbenicillin acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has been used primarily in hospital settings for severe infections caused by susceptible organisms, especially those resistant to other penicillins due to its extended spectrum of activity against Gram-negative pathogens. Sulbenicillin may be combined with beta-lactamase inhibitors or aminoglycosides for synergistic effects in certain clinical scenarios.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulbenicillin.